Health Insurance Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
sanofi-aventis
New data support long-term use of Ambien CRTM (zolpidem tartrate extended- release)
August 13th, 2006
sanofi-aventis (SNY) announced results from a study that demonstrated Ambien CR is well-tolerated and effective in improving sleep onset and maintenance for up to six months in patients with chronic primary insomnia when taken as needed for up to seven nights per week. According to the data, Ambien CR demonstrated significant improvements in total sleep time, sleep onset latency, wake time after sleep onset, sleep quality and number of awakenings versus placebo. Patients also did not experience rebound insomnia following discontinuation. This multicenter, double-blind, placebo-controlled evaluation of Ambien CR 12.5mg involved 1,018 adult volunteers...
Source: Health Insurance Law Weekly (2006-08-13)
|
